Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Prostate Cancer

Free Subscription 03.08.2026 1 BJU Int 1 BMC Cancer 1 Br J Radiol 2 Cancer Lett 1 Clin Cancer Res 1 Eur J Radiol 2 Eur Urol 1 Int J Radiat Oncol Biol Phys 3 Int J Urol 2 J Clin Oncol 2 J Nucl Med 3 N Engl J Med 2 Oncogene 1 Oncology (Williston Park) 1 PLoS One 1 Proc Natl Acad Sci U S A 3 Radiology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BJU Int

1. ULERI A, Cella L, Long-Depaquit T, Sordelli F, et al
   Active surveillance for intermediate-risk prostate cancer: a systematic review and pooled analysis.
   BJU Int. 2026 Jul 26. doi: 10.1111/bju.70388.
   PubMed         Abstract available
   
   

   
   BMC Cancer

2. ZHANG X, Chen M, Zou P, Kanchana K, et al
   Editorial Expression of Concern: Curcumin analog WZ35 induced cell death via ROS-dependent ER stress and G2/M cell cycle arrest in human prostate cancer cells.
   BMC Cancer. 2026;26:898.
   PubMed        
   
   

   
   Br J Radiol

3. THOMPSON C, Withey SJ, Tunariu N, Parker C, et al
   Use of whole-body MRI to evaluate residual tumour burden after initial systemic therapy in polymetastatic hormone-sensitive prostate cancer.
   Br J Radiol. 2026 Jul 28:tqag168. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Cancer Lett

4. DURAKI A, Krieger KD, Celada S, Holt RA, et al
   Vitamin D deficiency alters prostate epithelial differentiation and increases prostate cancer aggressiveness in ex vivo and in vivo models.
   Cancer Lett. 2026 Jul 31:218732. doi: 10.1016/j.canlet.2026.218732.
   PubMed         Abstract available
   
   
5. CHEN Y, Lai J, Chen J, Zhou Z, et al
   The FGFRL1-FASN axis regulates neuroendocrine lineage transdifferentiation by modulating fatty acid synthesis in AR pathway-independent prostate cancer.
   Cancer Lett. 2026 Jul 28:218769. doi: 10.1016/j.canlet.2026.218769.
   PubMed         Abstract available
   
   

   
   Clin Cancer Res

6. ZHAO SG, Holmberg E, Lundstedt D, Killander F, et al
   Investigation of a prostate cancer radiation response signature in the breast cancer SweBCG91RT randomized trial.
   Clin Cancer Res. 2026 Jul 30. doi: 10.1158/1078-0432.CCR-26-1455.
   PubMed         Abstract available
   
   

   
   Eur J Radiol

7. CUMMINGS C, Allen C, Dickinson L, Pendse D, et al
   Can prostate cancer be diagnosed with near certainty on MRI?
   Eur J Radiol. 2026;204:113107.
   PubMed         Abstract available
   
   

   
   Eur Urol

8. SANTIAGO I, Rivas JG
   Re: EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer.
   Eur Urol. 2026 Jul 25:S0302-2838(26)02285-2. doi: 10.1016/j.eururo.2026.
   PubMed        
   
   
9. KISHAN AU, Sun Y, Parker CC, Sargos P, et al
   Influence of Adverse Pathologic Features on Potential Benefit of Hormone Therapy Use with Postoperative Radiotherapy in Recurrent Prostate Cancer: An Individual Patient Data Meta-analysis.
   Eur Urol. 2026 Jul 28:S0302-2838(26)02270-0. doi: 10.1016/j.eururo.2026.
   PubMed         Abstract available
   
   

   
   Int J Radiat Oncol Biol Phys

10. MENDENHALL NP, Bryant CM, Katz AJ, Chen R, et al
    Can Engagement aid in design and accrual on Clinical Trials? Observations from COMPPARE - A Prospective Comparison of Outcomes with Proton and Photon Radiation in Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2026 Jul 29:S0360-3016(26)04063.
    PubMed         Abstract available
    
    

    
    Int J Urol

11. HATANO K, Watabe T, Hirata T, Konishi M, et al
    [(18)F]PSMA-1007 PET-Based Recurrence Site Distribution and Predictors of Metastatic Disease in Patients With Biochemical Recurrence of Prostate Cancer.
    Int J Urol. 2026;33:e70587.
    PubMed         Abstract available
    
    
12. SEKKELI S, Erbin A, Erdal FS, Gursoy E, et al
    The Impact of Dutasteride Treatment on Subsequent Multiparametric Prostate Magnetic Resonance Imaging Sequences and PI-RADS Score in Patients With PI-RADS 3 Lesions in the Transitional Zone.
    Int J Urol. 2026;33:e70585.
    PubMed         Abstract available
    
    
13. YAJIMA S, Yoshida S, Chen W, Fukushima H, et al
    Exploratory Time-Dependent Patterns in Estimated Treatment Effect of Talazoparib Plus Enzalutamide in HRR Non-Deficient or Unknown Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the TALAPRO-2 Trial.
    Int J Urol. 2026;33:e70582.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

14. ARMSTRONG AJ, Azad AA, Saad F, Hussain M, et al
    Reply to: Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide.
    J Clin Oncol. 2026 Jul 31:JCO2601500. doi: 10.1200/JCO-26-01500.
    PubMed        
    
    
15. ORUC A, Erol M
    Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide.
    J Clin Oncol. 2026 Jul 31:JCO2600962. doi: 10.1200/JCO-26-00962.
    PubMed        
    
    

    
    J Nucl Med

16. ELLS Z, Meyer C, Masri K, Ryhiner M, et al
    Tumor and Organ Dose Estimates from (177)Lu-PSMA-617 Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: Results from the RESIST-PC Phase 2 Trial.
    J Nucl Med. 2026 Jul 30:jnumed.126.272574. doi: 10.2967/jnumed.126.272574.
    PubMed         Abstract available
    
    
17. MILLER SR, Chung DH, Gonzalez RT, Jackson WC, et al
    Impact of PSMA PET Staging on Initial Treatment in Newly Diagnosed Prostate Cancer.
    J Nucl Med. 2025;66:1891-1897.
    PubMed         Abstract available
    
    

    
    N Engl J Med

18. LANGLEY RE, Gilbert DC, Nankivell M
    Transdermal Estradiol Patches in Prostate Cancer. Reply.
    N Engl J Med. 2026;395:517-518.
    PubMed        
    
    
19. GROSSMANN M, Russell N
    Transdermal Estradiol Patches in Prostate Cancer.
    N Engl J Med. 2026;395:517.
    PubMed        
    
    
20. SEARS C, Schuller L
    Transdermal Estradiol Patches in Prostate Cancer.
    N Engl J Med. 2026;395:517.
    PubMed        
    
    

    
    Oncogene

21. GAO Y, Liu Y, Ye X, Liu A, et al
    Super enhancer-driven transcriptional reprogramming promotes abiraterone resistance via neuroendocrine transition and ferroptosis evasion in castration-resistant prostate cancer.
    Oncogene. 2026 Jul 29. doi: 10.1038/s41388-026-03900.
    PubMed         Abstract available
    
    
22. ZAALBERG A, Lacoste A, Minnee E, Mayayo-Peralta I, et al
    A genome-wide CRISPR screen in human prostate cancer cells reveals drivers of macrophage-mediated cell killing and positions AR as a tumor-intrinsic immunomodulator.
    Oncogene. 2026 Jul 28. doi: 10.1038/s41388-026-03912.
    PubMed         Abstract available
    
    

    
    Oncology (Williston Park)

23. RODRIGUEZ-OLIVARES JL, Mauricio Mora Pineda Md, Beas-Lozano E, Alec Seidman-Sorsby Md, et al
    Homologous Recombination and Mismatch Repair Assessment in Men With Advanced Prostate Cancer: A Cross-Sectional Study From a Center in Mexico City.
    Oncology (Williston Park). 2026;40.
    PubMed         Abstract available
    
    

    
    PLoS One

24. CHEN X, Su W, Zhou Q, Qi Y, et al
    Concordant RNA-protein evidence and human tissue metabolomics prioritize UPP1-associated nucleotide remodeling in prostate cancer.
    PLoS One. 2026;21:e0354354.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

25. RAO X, Allison DB, Flight RM, Lin P, et al
    PLK1-mediated phosphorylation of PHGDH reprograms serine metabolism in advanced prostate cancer.
    Proc Natl Acad Sci U S A. 2026;123:e2618349123.
    PubMed         Abstract available
    
    

    
    Radiology

26. NEZAMI N, Unger KR
    When Electrons Cooperate with Photons: Prostate Cancer Loses Its Sanctuary.
    Radiology. 2026;320:e261563.
    PubMed        
    
    
27. MCCLURE TD, Wang S, Ballman KV, Diven M, et al
    Combination of Radiation Therapy and Irreversible Electroporation for Intermediate-Risk Prostate Cancer (RTIRE): A Phase 1 Trial.
    Radiology. 2026;320:e250848.
    PubMed         Abstract available
    
    
28. ULANER GA, Bassett JC, Reddy R, Thomsen B, et al
    Erratum for: (61)Cu-NODAGA Prostate-specific Membrane Antigen Imaging and Therapy for Prostate Cancer: Phase 1 Trial of a New Class of (61)Cu-labeled PET Radiotracers.
    Radiology. 2026;320:e269013.
    PubMed        
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum